Many CLS members deliver progress and treatments to address rare diseases that impact up to 30 million Americans. Learn more about what CLS members are doing around rare disease and drug development, what the future holds for advancements in this space and how we can improve access to innovative rare disease treatments.
Encapsulating the Future of Rare Diseases
Policy considerations for advancing rare disease therapies after the IRA
Realizing Potential through Rare Disease Education
The promise of new technologies to treat rare diseases will be realized only if we revolutionize our regulatory approach